Michele Cleary joined The Mark Foundation as CEO in January 2017. Prior to that, she was Vice President of Clinical Translation Technologies & Operations at Bristol-Myers Squibb where she led biomarker research for cancer and other diseases. Before joining BMS, Michele served in several leadership roles at Merck & Co., Inc., overseeing the development and application of innovative platforms for understanding cancer pathways, identification of new therapeutic approaches for multiple diseases, and functional validation of novel drug targets identified through human genetics. At Merck, her teams also conducted pioneering work on microRNAs as therapeutic targets and biomarkers in cancer. Michele received a PhD in Molecular Microbiology and Genetics from Stony Brook University and completed graduate research at Cold Spring Harbor Laboratory followed by postdoctoral training at Princeton University. She is co-author of more than 50 primary research papers and co-inventor on multiple patents with direct application to cancer drug development.